Article citationsMore>>

G. Legrand, S. Humez, C. Slomianny, E. Dewailly, F. Vanden Abeele, P. Mariot, F. Wuytack and N. Prevarskaya, “Ca2+ Pools and Cell Growth. Evidence for Sarcoendoplasmic Ca2+-ATPases 2B Involvement in Human Prostate Cancer Cell Growth Control,” The Journal of Biological Chemistry, Vol. 276, No. 50, 2001, pp. 47609-47614. doi:10.1074/jbc.M107011200

has been cited by the following article:

• TITLE: Exploiting MCF-7 Cells’ Calcium Dependence with Interlaced Therapy

  AUTHORS: Jonathan Pottle, Chengrong Sun, Lloyd Gray, Ming Li

  KEYWORDS: Breast Cancer; Calcium; Calcium Channel Blockers; Ion Channels; Interlaced Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.7A, July 22, 2013

  ABSTRACT: The purpose of this study is to demonstrate MCF-7 cells’ dependence on calcium for growth and to exploit that dependence to improve chemotherapy efficacy. Fura-2 fluorescence imaging shows that MCF-7 cells maintain a higher basal intracellular calcium concentration than non-tumorigenic MCF-10A cells. Blocking T-type calcium channels with mibefradil reduced MCF-7 intracellular calcium concentration. Flow cytometry shows that knocking down T-type calcium channel expression with siRNA caused an increase in MCF-7 cells in G1 phase and a decrease in cells in S phase. Proliferation assays of MCF-7 cells treated with EGTA and thapsigargin reveal the dependence of MCF-7 cell growth on extracellular and intracellular calcium sources, respectively. In vitro, interlaced treatment that alternated the T-type calcium channel blocker NNC-55-0396 with paclitaxel more effectively reduced MCF-7 cell number than chemotherapy alone. In a mouse in vivo model, interlaced mibefradil and paclitaxel more effectively reduced MCF-7 xenograft size than chemotherapy alone. These findings indicate that MCF-7 cells are dependent on calcium for proliferation, particularly in passing the G1/S cell cycle checkpoint. Further, this dependence on calcium can be exploited by alternating treatment with T-type calcium channel blockers with paclitaxel in an interlaced therapy scheme that increases the efficacy of the chemotherapy.